RJT
SRRA

Raymond James Trust’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Raymond James Trust’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-548
Closed -$8K – 986
2019
Q4 		$8K Sell
548
-75
-12% -$979 ﹤0.01% 960
2019
Q3 		$10K Hold
623
– – ﹤0.01% 938
2019
Q2 		$14K Sell
623
-283
-31% -$13.7K ﹤0.01% 909
2019
Q1 		$62K Hold
906
– – ﹤0.01% 866
2018
Q4 		$48K Hold
906
– – ﹤0.01% 813
2018
Q3 		$61K Hold
906
– – ﹤0.01% 884
2018
Q2 		$107K Hold
906
– – 0.01% 837
2018
Q1 		$75K Buy
906
+180
+25% +$20.4K 0.01% 718
2017
Q4 		$108K Hold
726
– – 0.01% 727
2017
Q3 		$45K Hold
726
– – ﹤0.01% 728
2017
Q2 		$34K Hold
726
– – ﹤0.01% 720
2017
Q1 		$44K Hold
726
– – ﹤0.01% 701
2016
Q4 		$43K Buy
726
+436
+150% +$27.2K ﹤0.01% 705
2016
Q3 		$21K Hold
290
– – ﹤0.01% 679
2016
Q2 		$23K Buy
+290
New +$55.3K ﹤0.01% 676

Other funds holding SRRA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James Trust's SRRA Position: Q1 2020 in Review

Raymond James Trust sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q1 2020, closing a stake of 548 shares — an estimated $8K sold.

Raymond James Trust first reported a position in SRRA in Q2 2016 and held it in 15 quarters. The position peaked at $108K in Q4 2017. 22 funds tracked by Wall St. Rank hold SRRA as of Q1 2020.

  • Raymond James Trust reported no remaining Sierra Oncology, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Raymond James Trust sold 548 Sierra Oncology, Inc. Common Stock shares in Q1 2020, an estimated $8K.
  • Raymond James Trust first reported a position in Sierra Oncology, Inc. Common Stock in Q2 2016 and held it in 15 quarters.
  • Raymond James Trust's Sierra Oncology, Inc. Common Stock position peaked at $108K in Q4 2017.
  • 22 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q1 2020.

Based on Raymond James Trust's 13F filing for Q1 2020, filed 17 Apr 2020.